Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
The trial confirms ALE.F02’s good safety profile, exposure and target biological activity BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology...



















